Target intelligence / Profile preview

Beta-mammal toxin Ct1a (Ct1a) (Ct1a)

Target
Ct1a
Molecular classification
Scorpion toxin, Beta-mammal toxin, Voltage-gated sodium channel modulator
01

Overview

Centruroides tecomanus Ct1a is a potent beta-mammal toxin isolated from the venom of the Mexican scorpion Centruroides tecomanus. It primarily acts as a modulator of voltage-gated sodium channels, with a high affinity for the Nav1.6 subtype. By binding to site 4 of these channels, Ct1a shifts the voltage-dependence of activation toward more negative potentials, which leads to persistent channel opening and repetitive neuronal firing. This mechanism is responsible for the severe neurotoxic symptoms observed during envenomation, including pain, paresthesia, and potentially fatal systemic effects. In therapeutic research, Ct1a is a target for the development of recombinant antivenoms and single-chain antibody fragments (scFvs) designed to neutralize its toxic effects. Additionally, it serves as a valuable pharmacological tool for studying the role of Nav1.6 channels in neuronal excitability and diseases such as Parkinson's and chronic pain.

Other names
Beta-toxin Clt1Neurotoxin 1Toxin II.20.3.4Ct1
02

Mechanism of action

Neutralization of the toxin's activity through high-affinity binding by single-chain variable fragments (scFvs), which prevents the toxin from interacting with site 4 of voltage-gated sodium channels.

03

Biological functions

Sodium channel modulationNeurotransmission regulationDefense response
04

Disease associations

ScorpionismEnvenomation
05

Safety considerations

NeurotoxicityLethality in mammalsCardiovascular distressRespiratory failure
06

Interacting drugs

scFv 10FG2

2 more in the full profile.

Beyond the preview

Go deeper on Beta-mammal toxin Ct1a (Ct1a) (Ct1a).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beta-mammal toxin Ct1a (Ct1a) (Ct1a).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call